Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving hydrolase
Reexamination Certificate
2007-05-15
2007-05-15
Saidha, Tekchand (Department: 1652)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving hydrolase
C435S004000, C435S198000, C435S252300, C435S320100
Reexamination Certificate
active
10973467
ABSTRACT:
The enzyme Lp-PLA2in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2in therapy and a method of screening compounds to identify those compounds.
REFERENCES:
patent: 5019508 (1991-05-01), Johnson et al.
patent: 5108899 (1992-04-01), Allen
patent: 5210017 (1993-05-01), Carlsson et al.
patent: 5279957 (1994-01-01), Gross
patent: 5527698 (1996-06-01), Knopf et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5532152 (1996-07-01), Cousens et al.
patent: 5605801 (1997-02-01), Cousens et al.
patent: 5641669 (1997-06-01), Cousens et al.
patent: 5656431 (1997-08-01), Cousens et al.
patent: 5698403 (1997-12-01), Cousens et al.
patent: 5847088 (1998-12-01), Cousens et al.
patent: 5880273 (1999-03-01), Adachi et al.
patent: 5968818 (1999-10-01), Gloger et al.
patent: 5977308 (1999-11-01), Cousens et al.
patent: 5981252 (1999-11-01), MacPhee et al.
patent: 6045794 (2000-04-01), Cousens et al.
patent: 6099836 (2000-08-01), Cousens et al.
patent: 6146625 (2000-11-01), Cousens et al.
patent: 6177257 (2001-01-01), Macphee et al.
patent: 6203790 (2001-03-01), Cousens et al.
patent: 7045329 (2006-05-01), MacPhee et al.
patent: 7052862 (2006-05-01), MacPhee et al.
patent: 359425 (1989-08-01), None
patent: 509719 (1992-10-01), None
patent: 658205 (2000-03-01), None
patent: 673426 (2001-06-01), None
patent: 04346797 (1988-08-01), None
patent: 07059597 (1989-10-01), None
patent: 04346797 (1992-12-01), None
patent: 07059597 (1995-03-01), None
patent: 10017600 (1998-01-01), None
patent: WO 89/09818 (1989-10-01), None
patent: WO 94/20069 (1994-09-01), None
patent: WO 95/00649 (1995-01-01), None
patent: WO 95/09921 (1995-04-01), None
patent: WO 97/12984 (1997-04-01), None
patent: WO 98/44158 (1998-10-01), None
patent: WO 99/09147 (1999-02-01), None
patent: WO 99/64627 (1999-12-01), None
patent: WO 00/24910 (2000-05-01), None
patent: WO 00/32808 (2000-06-01), None
Yamamoto et al. (1990) Formation of lipid hydroperoxides in the cupric ion-induced oxidation of plasma and low density lipoprotein. Oxid. Damage Repair, Int. Soc. Free Radical Res. Bienn. Meeting. Meeting Date 1990, pp. 287-291. Editor: K. J. A. Da, Jan. 1990.
Stafforini et al., “The Platelet-activating Factor Acetylhydrolase from human erythrocytes”, Journal of Biological Chemistry 1993 vol. 268; 6; 3856-3865.
Stafforini et al., “Platelet activating factor acetylhydrolase from human plasma”, Methods in Enzymology1990 187: 344-57. Kohler G, et al., Nature 256:495-497 (1975).
Sevier, Ed, et al., Clinical Chem. 27:1797-1806 (1981).
Chandrakumar NS, et al.; :Stereospecific Synthesis of Ehter Phospholipids. Preparation of a-Alkyl-2-(acylamino)-2 deoxyglycerophosphoryl cholines, J. Org. Chem., 1197-1202 (1983).
Ponpipom MM, et al., Synthesis of Azide and Amide Analogs of Platelet-Activating Factors and Related Derivatives, Chem. Phys. Lipids;35:29-37 (1984).
Stafforini D, et al., “Human plasma platelet-activating factor acetylhydrolase,” J. Biol. Chem. 262(9): 4224-4230 (1987).
Stafforini D, et al. “Human macrophages secrete plate-activating factor actylhydrolase,” J. Biol. Chem. 265(17):9682-9687 (1990).
Langlais J. et al., Platelet-activating factor acetyl-hydrolase in human semen:a novel decapacitation factor? Biol. of Reprod. 44 (Suppl. 1):94 (1991).
San H, et al. “Safety and Short Term Toxicity of a Novel and Cationic Formulation for Human Gene Therapy,” Human Gene Therapy: 781-798 (1993).
Kim UT, et al. “Synthesis of Phospholipid Head groups via Nucleophilic Ring Opening of 1.3.2-Dioxaphospholanes,” J. Chem. Commun.: 70-71 (1993).
Christoffersen R, et al. “Ribozymes as Human Theraputic Agents,” J. of Medicinal Chem.: 2023-2037 (1994).
Stull R, et al., “Antigene, Ribozyme, and Aptomer Nucleic Acid Drugs: Progress and Prospects,” Pharm. Res. 1995.
Kohler G, et al., 256:495-497 (1975).
U.S. Appl. No. 08/886,152, filed Jun. 18, 1996, related to ref. AW of Oct. 26, 2004 IDS.
Hirashima et al., “Platelet-activating factor (PAF) concentration and PAF acetylhydrolase activity in cerebrospinal fluid of patients with subarachnoid hemorrhage”, J. Neurosurg 1994 80:31-36.
Kuby, Janis, “Immunology” 1991 W.H. Freeman 80-83.
Satoh et al., “Platelet-Activating Factor Acetylhydrolase in Plasma Lipoproteins From Patients With Ischemic Stroke”, Stroke 1992 23:1090-1092.
Satoh et al., “Activity of Platelet-Activating Factor (PAF) Acetylhydrolase in Plasma from Patients with Ischemic Cerebrovascular Disease”, Prostaglandins 1988 35 (5) :685-698.
Stafforini et al., “Platelet-activating Factor Acetylhydrolases”, J. Biol. Chem. 1997 272(29) :17895-17898.
Washburn, W.N. and Dennis, E.A. “Novel General Approach for the Assay and Inhibition of Hydrolytic Enzymes Utilizing Suicide-Inhibitory Bifunctional Linked substrates (SIBLINKS) :Exemplified in a Phospholipase Assay” J. Am. Chem. Soc. 1990 112:2040-2041.
Washburn, W.N. and Dennis, E.A. “Suicide-inhibitory Bifunctionally Linked Substrates (SIBLINKS) as Phospholipase A2 Inhibitors” J. Biol. Chem. 1991 266(8) :5042-5048.
Yoshida et al., “Platelet-activating factor acetylhydrolase activity in red blood cell-stroma from patients with cerebral thrombosis”, Acta Neurol Scand 1992 86:199-203.
Adjei et al., “Pulmonary Delivery of Peptide Drugs: Effect of Particle Size on Bioavailability of Leuprolide Acetate in Healthy Male Volunteers”, Pharm. Res. 7(6):565-569 (1990).
Basran et al., “Properties of Platelet Activating Factor (PAF-ACETHER) Which Suggest Involvement in Chronic Inflammation and Persistent Asthma”, Br. J. Pharmacol. 77:437 (1982).
Braquet et al., “Effect of Endothelin-1 on Blood Pressure and Bronchopulmonary System of the Guinea Pig”, J. Cardio. Pharm. 13 (Supp.5):S143-S146 (1989).
Brenner, “The Molecular Evolution of Genes and Proteins: A Tale of Two Serines”, Nature 334:528-530 (1988).
Campbell, Biology 3rd Ed., p. 104-106 (1993).
Capecchi, “Altering the Genome by Homologous Recombination”, Science 244:1288-1292 (1989).
Caplan et al., “Role of Platelet Activating Factor and Tumor Necrosis Factor-alpha in Neonatal NecrotizingEnterocolitis”, J. Pediatr. 116(6):960-964 (1990).
Chapus et al., “Minireview on Pancreatic Lipase and Colipase”, Biochimie 70:1223-1234 (1988).
deBoer et al., “The tac Promoter: A Functional Hybrid Derived from the trp and lac Promoters”, Proc. Natl. Acad. Sci. USA 80:21-25 (1983).
Debs et al., “Lung-Specific Delivery of Cytokines Induces Sustained Pulmonary and Systemic Immunomodulation in Rats”, J. Immunol. 140(10):3482-3488 (1988).
Denizot et al., “PAF-Acether and Acetylhydrolase in Stool of Patients with Crohn's Disease”, Digestive Diseases and Sciences 37(3):432-437 (1992).
Furukawa et al., “Platelet-activating Factor-induced Ischemic Bowel Necrosis: The Effect of Platelet-Activating Factor Acetylhydrolase”, Ped. Res. 34(2):237-241 (1993).
Grino J.M., “BN 52021:A Platelet Activating Factor Antagonist for Preventing Post-Transplant Renal Failure”, Ann. Int. Med. 121(5):345-347 (1994).
Hahn et al., “The Complete Sequences of Plasmids pFNeo and pMH-Neo: Convenient Expression Vectors for High-level Expression of Eukaryotic Genes in Hematopoietic Cell Lines”, Gene 127:267-268 (1993).
Harlow et al., “Antibodies: A Laboratory Manual”, Cold Spring Harbor Press, p. 423 (1988).
Handley et al., “Platelet Activating Factor and Inflammation in Atherogenesis: Targets for Drug Development”, Drug Dev. Res. 7:361-375 (1986).
Hattori et al., “The Catalytic Subunit of Bovine Brain Platelet-activating Factor Acetylhydrolase is a Novel Type of Serine Esterase”, J. Biol. Chem. 269(37):23150-23155 (1994).
Hattori et al., “Purification and Characterization of Bovine Brain Platelet-activating Fa
MacPhee Colin H.
Tew David Graham
Letts Nathan P.
Licata & Tyrrell P.C.
Saidha Tekchand
SmithKline Beecham P.L.C.
LandOfFree
Lipoprotein associated phospholipase A2, inhibitors thereof... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lipoprotein associated phospholipase A2, inhibitors thereof..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipoprotein associated phospholipase A2, inhibitors thereof... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3763984